Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $239,502.60 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Awny Samaan Botros Farajallah sold 14,006 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $239,502.60. Following the transaction, the insider owned 116,177 shares in the company, valued at approximately $1,986,626.70. This trade represents a 10.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $17.42 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock has a market cap of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. The stock has a 50-day moving average of $16.49 and a 200-day moving average of $17.13. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TAK. Valeo Financial Advisors LLC lifted its position in Takeda Pharmaceutical by 6.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after acquiring an additional 632 shares in the last quarter. Franklin Resources Inc. boosted its stake in Takeda Pharmaceutical by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after purchasing an additional 713 shares during the period. Abel Hall LLC increased its holdings in Takeda Pharmaceutical by 2.3% during the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after purchasing an additional 781 shares in the last quarter. Private Trust Co. NA increased its holdings in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after purchasing an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in shares of Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after purchasing an additional 786 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analysts Set New Price Targets

TAK has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Key Headlines Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.